Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies by Manuel Anguita, Mariano de la Figuera, Alejandro I Pérez Cabeza, Carmen Suarez Fernández

Get full text

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban by Francisco Marin, Marcelo Sanmartin Fernandez, Gonzalo Baron-Esquivias, Vivencio Barrios, Inaki Lekuona, Alejandro I Perez-Cabeza, Jaime Masjuan, Esther Recalde del Vigo, Jose Manuel Vazquez Rodriguez, Roman Freixa-Pamias, Vanessa Roldan Schilling, Fernando Arribas, Carles Rafols Priu, Manuel Anguita Sanchez

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study by Carmen Mora-Fernández, Adora Pérez, Anna Mollar, Anna Mollar, Patricia Palau, Martina Amiguet, Rafael de la Espriella, Juan Sanchis, Juan Sanchis, Jose Luis Górriz, María José Soler, Juan F. Navarro-González, Juan F. Navarro-González, Julio Núñez, Julio Núñez, DAPA-VO2 Investigators, Patricia Palau, Martina Amiguet, Eloy Domínguez, Clara Sastre, Anna Mollar, Julia Seller, Jose Manuel Garcia Pinilla, Ainoha Larumbe, Alfonso Valle, Juan Jose Gómez Doblas, Rafael de la Espriella, Gema Miñana, Ainhoa Robles Mezcua, Enrique Santas, Vicent Bodí, Juan Sanchis, Domingo Pascual-Figal, Jose Luis Górriz, Antonio Baýes-Genís, Jose Civera, Adriana Conesa, Rim Zakarne, Clara Jiménez Rubio, Alejandro I. Pérez Cabeza, Arancha Díaz Expósito, José David Martínez Carmona, Manuel Luna Morales, Francisco J. Zafra Sánchez, Ángel Montiel Trujillo, Herminio Morillas Climent, Julio Núñez

Get full text